Recombinant Mouse VEGFR2/Flk-1 His-tag Protein, CF

When Recombinant Mouse VEGFR2/KDR/Flk-1 (Catalog # 10095-KD) is immobilized at 0.5 μg/mL, 100 μL/well, Recombinant Mouse VEGF 164 (Catalog # 493-MV) binds with an ED50 of 0.015‑0.12 μg/mL.

2 μg/lane of Recombinant Mouse VEGFR2/KDR/Flk‑1 His-tag (Catalog # 10095-KD) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 120-132 kDa.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse VEGFR2/Flk-1 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse VEGFR2/KDR/Flk-1 His-tag (Catalog # 10095-KD) is immobilized at 0.5 μg/mL, 100 μL/well, the concentration of Recombinant Mouse VEGF 164 (Catalog # 493-MV) that produces 50% of the optimal binding response is 0.015-0.12 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse VEGFR2/KDR/Flk-1 protein
  Ala20-Glu762, with a C-terminal 6-His tag
• Accession #: P35918
• N-terminal Sequence: Ala20
• Structure / Form: Monomer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 844 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 120-132 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse VEGFR2/Flk-1 His-tag Protein, CF

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and a tyrosine kinase domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature mouse VEGFR2 is composed of a 743aa residue extracellular domain, a 21 aa residue transmembrane domain and a 584 aa residue cytoplasmic domain. The mature mouse VEGFR2 shares 80% and 93% sequence identity to human and rat VEGFR2. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2 binds VEGF with high affinity and is a potent VEGF antagonist (1, 2).

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA. 95:548.

Bioinformatics

• Uniprot:
  • P35918()